Diabetes & Metabolism Journal

Sulwon Lecture 2024

Basic and Translational Research
Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System: Il Rae Park, Yong Geun Chung, Kyu Chang Won; Diabetes Metab J. 2025;49(1):1-12. Published online January 1, 2025; DOI: https://doi.org/10.4093/dmj.2024.0796

14,865 View
530 Download
20 Web of Science
23 Crossref

Type 2 diabetes mellitus (T2DM) is marked by chronic hyperglycemia, gradually worsening β-cell failure, and insulin resistance. Glucotoxicity and oxidative stress cause β-cell failure by increasing reactive oxygen species (ROS) production, impairing insulin secretion, and disrupting transcription factors such as pancreatic and duodenal homeobox 1 (PDX-1) and musculoaponeurotic fibrosarcoma oncogene family A (MafA). Cluster determinant 36 (CD36), an essential glycoprotein responsible for fatty acid uptake, exacerbates oxidative stress and induces the apoptosis of β-cells under hyperglycemic conditions through pathways involving ceramide, thioredoxin-interacting protein (TXNIP), and Rac1-nicotinamide adenine dinucleotide phosphate oxidase (NOX)-mediated redoxosome formation. Targeting CD36 pathways has emerged as a promising therapeutic strategy. Oral hypoglycemic agents, such as metformin, teneligliptin, and pioglitazone, have shown protective effects on β-cells by enhancing antioxidant defenses. These agents reduce glucotoxicity via mechanisms such as suppressing CD36 expression and stabilizing mitochondrial function. Additionally, novel insights into the glutathione antioxidant system and its role in β-cell survival underscore its therapeutic potential. This review focuses on the key contribution of oxidative stress and CD36 to β-cell impairment, the therapeutic promise of antioxidants, and the need for further research to apply these findings in clinical practice. Promising strategies targeting these mechanisms may help preserve β-cell function and slow T2DM progression.

Citations

Citations to this article as recorded by

Small‐Molecule Sarco/Endoplasmic Reticulum Ca2+‐ATPase Activators Reverse Methylglyoxal‐Induced Inhibition through Nonantioxidant Mechanisms
Carlos Cruz‐Cortés, Silvia Micháliková, Petronela Rezbáriková, L. Michel Espinoza‐Fonseca, Jana Viskupičová
ChemMedChem.2026;[Epub] CrossRef
Bone Marrow Mesenchymal Stromal Cells and Their Derived Extracellular Vesicles Protect Pancreatic Beta‐TC‐6 Cells From Hypoxia‐Induced Injury via miR‐539‐3p‐Mediated Downregulation of CD36 Expression
Na Lin, Yaoyao Liang, Minying Tang, Fei Liu, Liuyan Chen, Lvying Wu, Yunfeng Fu, Zhuoyu Li, Lingfeng Zhu, Jin Chen, Yuelin Zhang
Stem Cells International.2026;[Epub] CrossRef
Potential Involvement of PI3K/AKT Signaling Pathway in the Protective Effects of Rhinacanthus nasutus Against Diabetic Nephropathy-Induced Oxidative Stress
Junyu Liu, Yehao Lin, Xudong Yi, Min Zhang, Pharkphoom Panichayupakaranant, Joseph Buhagiar, Haixia Chen
Antioxidants.2026; 15(2): 252. CrossRef
Amylin and parameters of carbohydrate and lipid metabolism in patients with type 2 diabetes mellitus in the Azerbaijani population
Z.G. Akhmedova, D.I. Kagramanova
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(1): 35. CrossRef
Advanced Studies in Molecular and Metabolic Mechanisms of Diabetes: Pathogenic Crosstalk, Biomarkers, and Translational Therapeutics
Iliyana Sazdova, Hristo Gagov, Nikola Hadzi-Petrushev, Marina Konaktchieva, Rossitza Konakchieva, Mitko Mladenov
Applied Sciences.2026; 16(6): 3027. CrossRef
Chlorogenic acid and gallic acid synergistically reduce hyperglycemia and hyperlipidemia in diabetic BALB/c mice
Mudassir Hassan, Muhammad Ali, Javaria Altaf, Faisal Saeed Awan
Scientific Reports.2026;[Epub] CrossRef
Effects of prolonged exposure to 2.45 GHz electromagnetic fields on mouse health over a 5-month period
Zhichun Lv, Yunqiang Wu, Ke Zhao, Jingjing Li, Huiying Gao, Xiongwei Zhao, Siyu Li, Anyu Xu, Jingfei Li, Yuyang Cai, Shensi Xiang, Hui Chen, Ronghua Yin, Miao Yu, Xiaoming Yang, Changyan Li
Ecotoxicology and Environmental Safety.2026; 315: 120106. CrossRef
CD36 serves as a potential drug-target to alleviate inflammation in atherosclerosis via leonurine-mediated blockade of its activation pocket
Ge Lin, Ai-Qiu Chi, Sheng-Yang Cai, Ya-Meng Zhang, Yu-Chen Ren, Xu Lu, Chen Sun, Xue-Pan Mu, Igor Ying Zhang, Jing-Wei Weng, Meng-Yao Li, Ying Chen, Yi Zhun Zhu, Bei-Bei Tao, Yi-Chun Zhu
Free Radical Biology and Medicine.2026; 251: 256. CrossRef
Biochemical Mechanisms of Cellular Stress Adaptation in the Pathogenesis of Chronic Diseases
Joanna Lemanowicz, Sylwester M. Kloska, Anetta Siwik-Ziomek, Paweł Kołaczyk, Urszula Wnuk Lipińska, Anna Kloska
Molecules.2026; 31(9): 1381. CrossRef
Mitochondrial dysfunction–driven inflammation and β-Cell apoptosis in type 2 diabetes mellitus: mechanistic insights and therapeutic implications
Satyam Yadav, Gautam Kumar, Sumit Kumar, Khadga Raj Aran, Sourabh Kosey
Molecular Biology Reports.2026;[Epub] CrossRef
Compensated But Failing: Early β‐Cell Dysfunction Under Normoglycemia in Children and Adolescents With Overweight and Obesity
Paulina Correa‐Burrows, Estela Blanco, Raquel Burrows
Diabetes/Metabolism Research and Reviews.2026;[Epub] CrossRef
Targeting PGC-1α by miRNA-374 Simultaneously Improve β-Cell Dysfunction and Suppress Hepatic Glucose Overproduction
Ji-Won Kim, Joonyub Lee, Young-Hye You, Chan-Hee Oh, Heon-Seok Park, Eun Young Lee, Seung-Hwan Lee, Seung-Hyun Ko, Ji-Ho Park, Kun-Ho Yoon
Diabetes & Metabolism Journal.2026; 50(3): 535. CrossRef
Network pharmacology and experimental approaches to elucidate the mechanism of Niruryadi Gulika in protecting pancreatic β-cells in Type 2 diabetes
Rajappan Chandra Satish Kumar, Chittaranjan Das, Dhayalan Kalavathy GokulRaj, Murali Krishna Prasad, Mothishwaran Bhuvaneshwaran, Kunka Mohanram Ramkumar
In Silico Research in Biomedicine.2026; 2: 100366. CrossRef
Metformin beyond Glycemic Control: New Mechanistic Insights and Expanding Therapeutic Horizons
Eugene Han, Jung Ho Nam, Insuk Lee, Cheol Ryong Ku, Yong-ho Lee
Diabetes & Metabolism Journal.2026; 50(3): 435. CrossRef
Molecular mechanisms and structure—activity relationships of natural polysaccharides in ameliorating type 2 diabetes mellitus: a comprehensive review
Ying Zhou, Ruodi Yang, Qingfeng Wang, Jiaxin Li, Yufeng Yang, Yan Shi, Juntong Liu
Frontiers in Nutrition.2026;[Epub] CrossRef
Cholesterol, high-density lipoprotein, and glucose (CHG) index and incident impaired fasting glucose in Chinese adults: a retrospective longitudinal cohort study
Duo Yang, Renzhe Lin, Sen Li, Shujun Ye, Zitian Luo, Huankai Zhang, Si Wu, Longsheng Zhang
Frontiers in Nutrition.2026;[Epub] CrossRef
Polygonatum sibiricum polysaccharides enhance pancreatic β-cell function in diabetic zebrafish by mitigating mitochondrial oxidative damage via the AMPK-SIRT1 pathway
Fan Lin, Wenjing Yu, Ping Li, Shuyao Tang, Yitong Ouyang, Liya Huang, Di Wu, Shaowu Cheng, Zhenyan Song
Frontiers in Nutrition.2025;[Epub] CrossRef
Melatonin Improves Lipid Homeostasis, Mitochondrial Biogenesis, and Antioxidant Defenses in the Liver of Prediabetic Rats
Milena Cremer de Souza, Maria Luisa Gonçalves Agneis, Karoliny Alves das Neves, Matheus Ribas de Almeida, Geórgia da Silva Feltran, Ellen Mayara Souza Cruz, João Paulo Ferreira Schoffen, Luiz Gustavo de Almeida Chuffa, Fábio Rodrigues Ferreira Seiva
International Journal of Molecular Sciences.2025; 26(10): 4652. CrossRef
From Glucotoxicity to Lung Injury: Emerging Perspectives on Diabetes-Associated Respiratory Complications
Hongmei Yu, Jie Liu, Xiaojuan He
Lung.2025;[Epub] CrossRef
Quercetin as an Anti-Diabetic Agent in Rodents—Is It Worth Testing in Humans?
Tomasz Szkudelski, Katarzyna Szkudelska, Aleksandra Łangowska
International Journal of Molecular Sciences.2025; 26(15): 7391. CrossRef
Preclinical Evaluation of 2-Aminobenzothiazole Derivatives: In Silico, In Vitro, and Preliminary In Vivo Studies as Diabetic Treatments and Their Complications
Natalia Reyes-Vallejo, Miguel Valdes, Adelfo Reyes-Ramírez, Juan Andres Alvarado-Salazar, Alejandro Cruz, Erik Andrade-Jorge, Jessica Elena Mendieta-Wejebe
Molecules.2025; 30(16): 3427. CrossRef
Metal organic frameworks (MOFs) synthesis and their use as a loading agent in oxidative stress-based diseases
Muhammad Saqib Saif, Sana Batool, Yusra Majeed, Asadullah, Tuba Tariq, Li Haitao, Yanjun Duan, Ghazala Mustafa, Murtaza Hasan
Journal of Environmental Chemical Engineering.2025; 13(5): 118725. CrossRef
Synergism of Synthetic Sulfonamides and Natural Antioxidants for the Management of Diabetes Mellitus Associated with Oxidative Stress
Ancuța Dinu (Iacob), Luminita-Georgeta Confederat, Ionut Dragostin, Ionela Daniela Morariu, Dana Tutunaru, Oana-Maria Dragostin
Current Issues in Molecular Biology.2025; 47(9): 709. CrossRef

Editorial

Does Rosuvastatin/Ezetimibe Combination Therapy Offer Potential Benefits for Glucose Metabolism beyond Lipid-Lowering Efficacy in T2DM?: Il Rae Park, Jun Sung Moon; Diabetes Metab J. 2024;48(3):387-389. Published online May 22, 2024; DOI: https://doi.org/10.4093/dmj.2024.0168

7,812 View
373 Download

PDF PubReader ePub

Original Articles

Drug Regimen
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study: Jun Sung Moon, Il Rae Park, Sang Soo Kim, Hye Soon Kim, Nam Hoon Kim, Sin Gon Kim, Seung Hyun Ko, Ji Hyun Lee, Inkyu Lee, Bo Kyeong Lee, Kyu Chang Won; Diabetes Metab J. 2023;47(6):818-825. Published online November 24, 2023; DOI: https://doi.org/10.4093/dmj.2023.0171

16,024 View
652 Download
14 Web of Science
16 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM).
Methods
This study was a randomized, multicenter, open, parallel phase 4 study, and enrolled T2DM subjects with an estimated 10-year ASCVD risk ≥7.5%. The primary endpoint was the low-density lipoprotein cholesterol (LDL-C) change rate after 24-week rosuvastatin 10 mg/ezetimibe 10 mg treatment was non-inferior to that of rosuvastatin 20 mg. The achievement proportion of 10-year ASCVD risk <7.5% or comprehensive lipid target (LDL-C <70 mg/dL, non-high-density lipoprotein cholesterol <100 mg/dL, and apolipoprotein B <80 mg/dL) without discontinuation, and several metabolic parameters were explored as secondary endpoints.
Results
A hundred and six participants were assigned to each group. Both groups showed significant reduction in % change of LDL-C from baseline at week 24 (–63.90±6.89 vs. –55.44±6.85, combination vs. monotherapy, p=0.0378; respectively), but the combination treatment was superior to high-intensity monotherapy in LDL-C change (%) from baseline (least square [LS] mean difference, –8.47; 95% confidence interval, –16.44 to –0.49; p=0.0378). The combination treatment showed a higher proportion of achieved comprehensive lipid targets rather than monotherapy (85.36% vs. 62.22% in monotherapy, p=0.015). The ezetimibe combination significantly improved homeostasis model assessment of β-cell function even without A1c changes (LS mean difference, 17.13; p=0.0185).
Conclusion
In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.

Citations

Citations to this article as recorded by

Comparative outcomes of moderate-intensity statin with ezetimibe vs high-intensity statin therapy: A retrospective observational cohort study
Junpil Yun, Seokhun Yang, Doyeon Hwang, Jeehoon Kang, Han-Mo Yang, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Jung-Kyu Han
Journal of Clinical Lipidology.2026; 20(1): 87. CrossRef
Pharmacokinetics of a single-pill combination of rosuvastatin and ezetimibe (2.5 mg/10 mg) in healthy Chinese subjects: an open-label, two-period, phase I study
Ying Wang, Jiaxiang Ding, Dongmei Cheng, Yuzhou Ding, Tonghao Zhang, Wang Hu, Xiaoni Wang, Xu Zhu, Yunqiu Xie, Huan Zhou
Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(5): 6861. CrossRef
Cardiovascular outcomes and adverse drug reactions associated with the use of ezetimibe in combination with a statin in diabetes mellitus patients with higher risk for myocardial infarction: a meta-analysis
Yan Zhou, Ji Jin
BMC Cardiovascular Disorders.2026;[Epub] CrossRef
Lipid metabolism in homeostasis and disease
Zhenghao Li, Wende Deng, Lanxuan Yang, Changheng Tang, Jian-Min Yue, Olivia Monteiro, Daniel T. Baptista-Hon, Ting Li
Signal Transduction and Targeted Therapy.2026;[Epub] CrossRef
Combined Ursolic Acid and Rosuvastatin Treatment Mitigates Inflammation and Oxidative Stress in Diabetic Nephropathy Model Cells
Yijing Zhou, Chengli Lou, Xiangjing Wang, Pingxin Hu, Xiuqin Xu
Critical Reviews in Immunology.2026; 46(1): 59. CrossRef
Clinical study on the effect of jejunoileal side-to-side anastomosis on metabolic parameters in patients with type 2 diabetes
Ji-Kui Wang, Di Zhang, Jin-Feng Wang, Wan-Lin Lu, Jing-Yuan Wang, Shi-Feng Liang, Ran Liu, Jing-Xin Jiang, Hong-Tao Li, Xuan Yang
World Journal of Diabetes.2025;[Epub] CrossRef
Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
Il Rae Park, Yong Geun Chung, Kyu Chang Won
Diabetes & Metabolism Journal.2025; 49(1): 1. CrossRef
Neuroprotective Effect of Rosuvastatin Calcium Combined with Hyperbaric Oxygen Mediated p38MAPK Pathway in Rats with Leukoaraiosis
Yafeng Shi, Gemin Zhu, Jun Yan, Linxin Zhang, Yongku Du, Zhuoqiong Bian, Jing Fan
Cell Biochemistry and Biophysics.2025; 83(3): 3205. CrossRef
Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials
Abdelrahman Mahmoud, Hazem Mohamed Salamah, Hazem Rezq, Yazan Al-Mohtasib, Ali Ashraf Salah Ahmed, Mohamed R. Abdelraouf, Ahmed Mazen Amin, Ahmed A. Ibrahim, Yasmine Adel Mohammed, Omar Ahmed Abdelwahab, Majd M. AlBarakat, Salem Elshenawy, Husam Abu Suili
Baylor University Medical Center Proceedings.2025; 38(4): 474. CrossRef
Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis
Shujie Zhang, Tingting Sun, Lina Song, Xiaodong Jin, Bo Li
European Journal of Medical Research.2025;[Epub] CrossRef
Effect of folic acid and vitamin B12 plus rosuvastatin in the treatment of coronary heart disease combined with hyperlipidemia
Hao Wang, Tiezheng Wang
Frontiers in Cardiovascular Medicine.2025;[Epub] CrossRef
Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus
Heinz Drexel, Andreas Festa, Thomas A Schmidt, Bianca Rocca, Dobromir Dobrev, Stefan Agewall, Juan Tamargo, Susanne Kaser
European Heart Journal - Cardiovascular Pharmacotherapy.2025; 11(8): 698. CrossRef
Does Rosuvastatin/Ezetimibe Combination Therapy Offer Potential Benefits for Glucose Metabolism beyond Lipid-Lowering Efficacy in T2DM?
Il Rae Park, Jun Sung Moon
Diabetes & Metabolism Journal.2024; 48(3): 387. CrossRef
Efficacy and safety of double-dose statin monotherapy versus moderate-intensity statin combined with ezetimibe dual therapy in diabetic patients: a systematic review and meta-analysis of randomized controlled trials
Aman Goyal, Muhammad Daoud Tariq, Hritvik Jain, Abhigan Babu Shrestha, Laveeza Fatima, Romana Riyaz, Hritik Raj Yadav, Darsh Safi, Abdul Qahar K. Yasinzai, Rozi Khan, Amir Humza Sohail, Mohamed Daoud, Abu Baker Sheikh
Cardiovascular Endocrinology & Metabolism.2024;[Epub] CrossRef
Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis
Lingyan Liu, Yongkun Deng, Lei Li, Xingbiao Yang, Zhaoheng Yin, Yong Lai, Jaspinder Kaur
PLOS ONE.2024; 19(11): e0310696. CrossRef
Pharmacokinetics and Bioequivalence Comparison of Two Fixed-Dose Combination of Rosuvastatin/Ezetimibe Formulations: A Randomized, Crossover, Open-Label Study in Healthy Volunteers
José Gregorio Chacón, Evelyn Peña, Alfredo Inatti
Journal of Biosciences and Medicines.2024; 12(10): 119. CrossRef

Drug Regimen
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension: Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon; Diabetes Metab J. 2023;47(6):808-817. Published online September 26, 2023; DOI: https://doi.org/10.4093/dmj.2022.0387

11,867 View
538 Download
6 Web of Science
7 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination.
Methods
In this multicenter randomized placebo-controlled phase 3 trial, patients with glycosylated hemoglobin (HbA1c) levels 7.0% to 10.5% (n=283) previously used DAPA 10 mg plus MET (≥1,000 mg) were randomly assigned to the evogliptin 5 mg once daily or placebo group (1:1). The primary endpoint was the difference in the HbA1c level from baseline at week 24, and exploratory endpoints included the efficacy and safety of evogliptin over 52 weeks (trial registration: ClinicalTrials.gov NCT04170998).
Results
Evogliptin add-on to DAPA/MET therapy was superior in HbA1c reduction compared to placebo at weeks 24 and 52 (least square [LS] mean difference, –0.65% and –0.55%; 95% confidence interval [CI], –0.79 to –0.51 and –0.71 to –0.39; P<0.0001). The proportion of patients achieving HbA1c <7% was higher in the triple combination group at week 52 (32.14% vs. 8.51% in placebo; odds ratio, 5.62; P<0.0001). Evogliptin significantly reduced the fasting glucose levels and mean daily glucose levels with improvement in homeostatic model assessment of β-cell function (LS mean difference, 9.04; 95% CI, 1.86 to 16.21; P=0.0138). Adverse events were similar between the groups, and no serious adverse drug reactions were reported in the evogliptin group.
Conclusion
Long-term triple combination with evogliptin added to DAPA/MET showed superior HbA1c reduction and glycemic control compared to placebo at 52 weeks and was well tolerated.

Citations

Citations to this article as recorded by

Clinical-economic assessment of the potential contribution of evogliptin to achieving the targets of the Federal project «Fight against diabetes mellitus» and reduction of population mortality
N. N. Avxentyev, A. S. Makarov, I. A. Karpova, V. V. Yavlyanskaya
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.2025; (4): 55. CrossRef
Design, synthesis, and biological evaluation of quinazolinone-dihydropyrimidinone as a potential anti-diabetic agent via GLUT4 translocation stimulation
Arvind Kumar Jaiswal, Ajay Kishor Kushawaha, Pawan kumar, Alisha Ansari, Nikita Chhikara, Hemlata bhatt, Sarita Katiyar, Ishbal Ahmad, Abhijit Deb Choudhury, Rabi Sankar Bhatta, Akhilesh K. Tamrakar, Koneni V. Sashidhara
European Journal of Medicinal Chemistry.2025; 288: 117366. CrossRef
Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation
Myung Jin Kim, Yun Kyung Cho, Sehee Kim, Jung Yoon Moon, Chang Hee Jung, Woo Je Lee
Diabetes, Obesity and Metabolism.2025; 27(9): 5019. CrossRef
Comparative efficacy and safety of Evogliptin in type 2 diabetes patients above and below 65 years
Jimi Kim, Young‐Seol Kim, You‐Cheol Hwang, Jung‐Eun Yim
Diabetes, Obesity and Metabolism.2025; 27(10): 6084. CrossRef
Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus (RECAM study)
Leili Gao, Linong Ji, Xin Yan, Zhifeng Cheng, Xin Zhang, Wenli Sun, Jianhua Ma, Weihong Song, Yu Liu, Xiaohong Lin, Wuyan Pang, Haixiang Cao, Bo Chen, Zhibin Li, Xianping Lu
Diabetes, Obesity and Metabolism.2025; 27(11): 6243. CrossRef
Triple oral therapy with metformin, DPP‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
Miao Yu, Tong Wang, Chun Xu, Yan Bi, Ling Gao, Guang Wang, Guangda Xiang, Yaoming Xue, Tao Yang, Deying Kang, Zhiguang Zhou, Lixin Guo, Xinhua Xiao
Diabetes, Obesity and Metabolism.2025; 27(S9): 3. CrossRef
Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study
In‐Kyung Jeong, Kyung Mook Choi, Kyung Ah Han, Kyoung‐Ah Kim, In Joo Kim, Seung Jin Han, Won Young Lee, Soon Jib Yoo
Diabetes, Obesity and Metabolism.2024; 26(11): 5065. CrossRef

First
Prev
Page of 1
Next
Last

Search